Washington, DC (January 9, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, has been named chairman of PhRMA’s board of directors. Duato formerly held the position of chairman-elect of the PhRMA board and succeeds George Scangos, who has stepped down as CEO of Biogen.
“I am pleased to welcome Joaquin Duato as PhRMA board chairman and thank George Scangos for his leadership,” said PhRMA president and CEO Stephen J. Ubl. “Through sustained investment in research and development, biopharmaceutical researchers and scientists have gained a better understanding of diseases and a greater ability to harness new scientific advances. Joaquin’s focus on our industry’s role in transforming lives will be crucial as we work with all stakeholders to make the health care system better and more responsive to the needs of patients.”
Duato has served as worldwide chairman, pharmaceuticals at Johnson & Johnson since January 2011. During his 28-year career at Johnson & Johnson, Duato has worked across the company’s pharmaceuticals and medical device business segments, held regional chairman roles and led local market businesses in a variety of countries and regions. As a dual citizen of Spain and the United States, he brings a unique international perspective to his work. Duato holds an undergraduate degree in economics and business, a Masters of Business Administration from ESADE, Barcelona and a Masters of International Management from Thunderbird, Phoenix. His passion for education can also be seen in his role as a member of the board of trustees for the international non-profit organization Save the Children.
“In the words of Dr. Paul Janssen, ‘the patients are waiting,’” said Duato. “Medicines are the best – and only – hope for treating and curing the most devastating diseases. At a time of extraordinary advances in medical discovery, I look forward to leading PhRMA and ensuring patients have access to the treatments of today and the cures of tomorrow.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
Contact: Lauren Levinson